CIK 0001590877
- Non-accelerated filer
- Smaller reporting company
REGENXBIO Inc.
Sign in to watch- Ticker
- RGNX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 471851754
- Phone
- +1 240-552-8181
- Business address
- 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
- Former names
- ReGenX Biosciences, LLC
- Open-market buys, last 90 days
- $949,381
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$949,381. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 8 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-05-24 | Abdun-Nabi Daniel Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 | ||
| 2017-05-24 | Tasse Daniel Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 | ||
| 2017-05-24 | HAYDEN DONALD J JR Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 | ||
| 2017-05-24 | BESHAR LUKE M Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 | ||
| 2017-05-24 | STUMP DAVID C Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 | ||
| 2017-05-24 | Fox Allan M. Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 | ||
| 2017-05-24 | KARABELAS ARGERIS N Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 | ||
| 2017-05-15 | HAYDEN DONALD J JR Director | Sale | −8,599 | $19.04 | $164K | 0 |
| 2017-05-15 | Vasista Vittal Chief Financial Officer | Sale | −3,100 | $19.07 | $59K | 110,612 |
| 2017-05-08 | HAYDEN DONALD J JR Director | Sale | −10,000 | $18.35 | $184K | 8,599 |
| 2017-05-01 | HAYDEN DONALD J JR Director | Exercise or conversion | +20,000 | $0.85 | $17K | 48,599 |
| 2017-05-01 | HAYDEN DONALD J JR Director | Sale | −4,738 | $21.34 | $101K | 43,861 |
| 2017-05-01 | HAYDEN DONALD J JR Director | Sale | −25,262 | $22.43 | $567K | 18,599 |
| 2017-05-01 | HAYDEN DONALD J JR Director | Exercise or conversion · Stock Option (Right to Buy) | −20,000 | 251,382 | ||
| 2017-04-24 | Mills Kenneth T. President and CEO | Sale | −14,045 | $20.94 | $294K | 126,395 |
| 2017-04-24 | Mills Kenneth T. President and CEO | Sale | −1,395 | $21.40 | $30K | 125,000 |
| 2017-04-24 | HAYDEN DONALD J JR Director | Sale | −10,000 | $20.98 | $210K | 28,599 |
| 2017-04-24 | Vasista Vittal Chief Financial Officer | Sale | −2,773 | $20.95 | $58K | 114,039 |
| 2017-04-24 | Vasista Vittal Chief Financial Officer | Sale | −327 | $21.42 | $7K | 113,712 |
| 2017-03-27 | Danos Olivier Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 |
Page 48 of 56 · 1,104 trades